Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

Majid Assadi; Samira Rezaei; Esmail Jafari; Seyed Javad Rekabpour; Mohammad Reza Ravanbod; Farshad Zohrabi; AbdulLatif Amini; Saeid Keshmiri; Habibollah Dadgar; Hojjat Ahmadzadehfar

doi:10.4103/wjnm.WJNM_20_19

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

World J Nucl Med. 2020 Feb 27;19(1):15-20. doi: 10.4103/wjnm.WJNM_20_19. eCollection 2020 Jan-Mar.

Affiliations

¹ Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran.
² Department of Oncology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran.
³ Department of Urology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran.
⁴ Department of Cardiology, Bushehr Heart Medical Center, Bushehr University of Medical Sciences, Bushehr, Iran.
⁵ Department of Anesthesiology (Division of Pain Management), Bushehr Heart Medical Center, Bushehr University of Medical Sciences, Bushehr, Iran.
⁶ Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran.
⁷ Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany.

Abstract

In recent years, lutetium-177 (¹⁷⁷Lu)-labeled prostate-specific membrane antigen (PSMA)-617 has become a promising new therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we report on an early experience of ¹⁷⁷Lu-PSMA therapy with an evaluation of its efficacy and safety in mCRPC patients. Twenty-one mCRPC patients with a mean age of 70.3 ± 9.6 (54-88)-year-old were treated with one to four therapy cycles (median two cycles) and administered activity of 3.7-29.6 GBq (mean of 15.4 GBq). A prostate-specific antigen (PSA) decline ≥ 50% was considered to be a biochemical response (BCR). To evaluate the clinical response, the Eastern Cooperative Oncology Group (ECOG) status was used. Within 2 weeks before and 1 and 2 months after each therapy cycle, hematology, renal function, liver status, alkaline phosphatase, and PSA were checked. The Common Terminology Criteria for Adverse Events was used for grading adverse events induced by ¹⁷⁷Lu-PSMA. Furthermore, overall survival (OS) was calculated and analyzed. During the treatment, a BCR was seen in 62% of patients; 19% of patients showed progression and 19% of patients showed stable disease. ECOG status was improved after treatment, and OS was 62.7 weeks. After the treatment, two patients showed Grade II toxicity of white blood cells, Grade I thrombocytopenia was observed in two patients, one patient showed Grade II toxicity in serum creatinine and transient Grade I toxicity in creatinine was seen in two patients. In total, our initial experience demonstrates that ¹⁷⁷Lu-PSMA therapy has the potential to positively affect the development and maturation of radioligand practices in selected mCRPC patients, even in resource limited, developing country environments. However, some challenges, such as practitioner training, poor initial acceptance by colleagues and financial concerns, particularly in developing nations, still exist.

Keywords: Biochemical response; lutetium-177 -prostate-specific membrane antigen; prostate cancer; radioligand therapy; toxicity.